Hepion Pharmaceuticals, Inc. Annual Report Summary

This summary offers a concise overview of Hepion Pharmaceuticals' performance and strategic developments for the fiscal year ended December 31, 2025. It provides investors with key insights into the company's financial health, operational activities, and principal risks.

Business Overview (What the Company Does) Hepion Pharmaceuticals operates as an early-stage biopharmaceutical company, primarily focusing on research and development (R&D) of novel drug candidates. Its core business involves advancing new treatments through the development pipeline. Hepion's strategy centers on internal discovery and development, supplemented by strategic collaborations or acquisitions, as demonstrated by the Merger Agreement and the NewDay Diagnostics LLC deal.

Financial Performance (Revenue, Profit, Year-over-Year Changes) As a pre-commercial, R&D-focused pharmaceutical company, Hepion Pharmaceuticals likely generated negligible or no revenue from product sales during fiscal year 2025. Consequently, the company reported a significant net loss and experienced substantial cash burn due to ongoing research and administrative expenses. The company's financial results reflect its status as a development-stage entity, heavily investing in R&D without commercialized products generating substantial revenue.

Risk Factors (Key Risks) Investing in Hepion Pharmaceuticals presents substantial risks:

• Extreme Dilution Risk: Frequent issuance of new shares, preferred stock, and various warrants significantly dilutes existing shareholders' ownership stakes, potentially depressing the stock price.
• Operational and R&D Failure Risk: As an R&D company, Hepion's success depends on the successful development, clinical testing, and regulatory approval of its drug candidates. Failure at any stage could render its investments worthless.
• Financial Viability and Going Concern Risk: With minimal revenue and high cash burn, the company faces a significant risk of failing to raise sufficient capital to continue operations, potentially leading to bankruptcy or business cessation.
• Market and Liquidity Risk: Trading on the OTC QB market typically means lower trading volume, higher price volatility, and greater difficulty for investors to buy or sell shares at desired prices. The extremely low market capitalization further amplifies these risks.
• Competitive Landscape: The pharmaceutical industry is highly competitive. Hepion faces challenges from larger, better-funded companies with established pipelines and market presence.
• Regulatory Risk: Drug development is subject to stringent and evolving regulatory requirements, which can cause delays, increase costs, or lead to outright rejection of drug candidates.

Management Discussion and Analysis (MD&A) Highlights Significant strategic activity marked fiscal year 2025. The company raised substantial capital through a Securities Purchase Agreement in July 2024 and a public offering of securities in January 2025. It also frequently issued various financial instruments, including preferred stock and multiple series of warrants (Series A, B, B1, B2 warrants). These activities were critical for funding ongoing operations and R&D, and they resulted in substantial shareholder dilution.

The Merger Agreement in January 2025 and the strategic deal with NewDay Diagnostics LLC in May 2025 represent significant operational highlights. The company also reported continued "In-Process Research and Development," indicating ongoing efforts to advance its drug candidates. The company's liquidity position and its ability to fund operations emphasize its reliance on external financing given the absence of product revenue.

Financial Health (Debt, Cash, Liquidity) Hepion's financial health hinges on its reliance on external capital. The company carries notes payable to banks, indicating a level of debt. Without revenue-generating products, the company's liquidity and ability to continue operations depend entirely on its success in raising additional capital through equity or debt financing. This creates a high degree of financial risk; any difficulty in securing future funding could severely impact its viability. The company's ability to continue as a "going concern" is highly dependent on securing additional financing.

Future Outlook (Guidance, Strategy) The company's future outlook directly links to the progress of its "In-Process Research and Development" and its ability to secure ongoing financing. The strategic direction, as indicated by the Merger Agreement and the NewDay Diagnostics LLC deal, suggests a focus on potential consolidation, expansion of capabilities, or diversification. A "subsequent event" noted in February 2026 indicates important developments occurred shortly after the fiscal year-end, which could provide crucial insights into the company's immediate future plans and financial standing.

Competitive Position Given its small size and R&D focus, Hepion operates as a niche or early-stage player within the broader pharmaceutical industry. Intense competition from large pharmaceutical companies, biotechnology firms, and academic institutions characterizes the biopharmaceutical industry. Competition centers on factors such as product efficacy, safety, price, market access, intellectual property, and the ability to attract and retain skilled personnel. The Merger Agreement and the NewDay Diagnostics LLC deal strongly suggest a strategic pivot or expansion, potentially aimed at strengthening its pipeline, market access, or technological capabilities.